子宮內膜癌的化學治療簡介

Chemotherapy for Endometrial Cancer

李耀泰(Yiu-Tai Li) ； 鄭文雄(Wen-Hsiung Chen) ； 陳福民(Fu-Min Chen) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2007年2期 (2007/10) Pp. 18-25

https://doi.org/10.7010/JGO.200710.0018

摘要

子宮內膜癌之治療，主要是以手術治療切除病灶，但如有局部轉移，常以放射線治療，許多晚期和從發性病灶，則多以化學治療。文獻上，治療子宮內膜癌之化學藥物，有效率差異很大。單一化學治療藥物，如cisplatin、carboplatin、doxorubicin和topotecan有效率都可＞20%，而以paclitaxel爲主結合數種化療藥物之治療，有效率在40-60%之間。化學治療之效果，受到曾否有放射線治療和化學治療失敗之影響。現階段需要更有效之藥物和藥方，亦需要考慮使用毒性較低藥物，如taxenes和carboplatin，希望能帶來更好的結果和較少之副作用。

關鍵字

子宮內膜癌 ； 化學治療

並列摘要

The early stage endometrial cancer are usually cured with surgery. Isolated pelvic recurrences are treated with radiation, whereas most other patients with advanced or recurrent disease receive systemic therapy. Response rates to systemic therapy reported in the literature vary considerably. For single agents, including cisplatin, carboplatin, topotecan, and doxorubicin, achieve response rates greater than 20%, and paclitaxel combination chemotherapy is associated with response rates of 40-60%. There is an obvious need for more effective therapies. In addition, the use of less toxic combinations including the taxenes and carboplatin are of interest and require further study.

並列關鍵字

Chemotherapy ； Endometrial cancer